NLS Pharmaceutics and Kadimastem merger aims to redefine diabetes treatment with multi-target therapies

NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company specialising in therapies for rare and complex central nervous system disorders, is set to merge with Kadimastem Ltd., an Israeli clinical-stage cell therapy company focused on neurodegenerative diseases and diabetes. This strategic merger is positioned to create a new force in diabetes innovation, offering a comprehensive approach that extends beyond conventional therapies. By combining pharmaceutical advancements with regenerative cell therapy, the companies aim to transform how diabetes is treated, addressing not just glucose levels but the systemic complications often overlooked in current treatments.

Moving beyond traditional diabetes treatments

While GLP-1 receptor agonists have been pivotal in managing type 2 diabetes, their limitations are becoming increasingly evident. These therapies primarily target blood sugar control and weight management, leaving critical gaps in addressing the broader, systemic effects of diabetes. Issues such as neuroinflammation, insulin resistance, and metabolic instability remain largely untreated, contributing to long-term complications that diminish patient quality of life.

Moreover, GLP-1 therapies are associated with gastrointestinal side effects, tolerance concerns, and questionable long-term safety profiles. As the prevalence of diabetes continues to rise globally, there is an urgent need for more comprehensive treatments that tackle both metabolic dysfunction and systemic diabetes complications. The anticipated merger between NLS Pharmaceutics and Kadimastem seeks to address these unmet needs by introducing a multi-target therapeutic approach designed to treat diabetes as a complex, multi-systemic disease.

Introducing DOXA: A breakthrough in multi-target diabetes treatment

At the forefront of this transformative strategy is DOXA (Dual Orexin and Multi-Pathway Modulation), a next-generation therapeutic platform developed by NLS Pharmaceutics. Unlike traditional diabetes drugs that focus solely on insulin regulation, DOXA aims to deliver a holistic treatment by targeting both metabolic pathways and neurological functions. This innovative approach is designed to improve not only glucose metabolism but also cognitive health, energy balance, and overall metabolic resilience.

DOXA’s multi-pathway strategy addresses the interconnected nature of diabetes and conditions such as diabetes-associated neurological disorders. These disorders, which include cognitive decline, sleep disturbances, and neurodegenerative issues, are increasingly recognised as major complications of diabetes. By focusing on neuroprotective mechanisms alongside metabolic regulation, DOXA represents a significant advancement in diabetes care, potentially modifying the course of the disease rather than simply managing its symptoms.

The science behind DOXA’s innovative approach

The development of DOXA is rooted in extensive preclinical research, which has demonstrated its potential to improve metabolic health while mitigating neurological complications associated with diabetes. DOXA operates through several mechanisms that work synergistically to restore balance within the body’s complex biological systems.

This multi-target approach is designed to address key issues such as neuroinflammation, oxidative stress, and insulin resistance—all of which contribute to the progression of diabetes and its related complications. By targeting these pathways, DOXA not only improves glucose metabolism but also enhances neuroprotection and metabolic stability, offering a comprehensive solution for managing diabetes.

Preclinical studies, which will be presented at the 2025 ASCP Annual Meeting, have shown that DOXA can significantly reduce inflammatory markers, improve cognitive function, and enhance insulin sensitivity. These findings suggest that DOXA has the potential to outperform existing therapies, particularly when used in combination with regenerative treatments such as islet transplantation.

A merger designed to accelerate diabetes innovation

The merger between NLS Pharmaceutics and Kadimastem represents a strategic alignment of complementary technologies and expertise. NLS Pharmaceutics brings its advanced pharmaceutical development capabilities, while Kadimastem contributes its cutting-edge work in cell therapy. Together, these companies aim to create a robust platform for addressing the full spectrum of diabetes-related health challenges.

This collaboration is expected to drive the development of therapies that are not only more effective but also capable of providing long-term benefits for patients. By leveraging their combined resources, the merged entity will be well-positioned to accelerate clinical research, streamline regulatory pathways, and bring innovative treatments to market more efficiently.

The future of diabetes treatment: Addressing systemic diabetes complications

Diabetes is increasingly recognised as a disease that affects multiple organ systems, not just the pancreas. The condition is linked to a range of complications, including cardiovascular disease, neuropathy, retinopathy, and kidney failure. In addition, emerging research has highlighted the connection between diabetes and neurodegenerative disorders, sleep disturbances, and mood disorders. These systemic diabetes complications underscore the need for treatment approaches that go beyond glucose control to address the root causes of these issues.

The NLS Pharmaceutics-Kadimastem merger is poised to meet this challenge head-on. By integrating pharmaceutical innovations with regenerative medicine, the companies aim to develop therapies that not only manage blood sugar levels but also improve neurological function, metabolic health, and overall quality of life for patients.

This holistic approach reflects a growing trend in diabetes research, which emphasises the importance of treating the disease as a complex, multi-systemic condition. As part of this strategy, the companies are committed to exploring new therapeutic targets, advancing clinical trials, and collaborating with healthcare providers to ensure that their treatments address the real-world needs of patients.

Paving the way for next-generation diabetes therapies

The anticipated merger between NLS Pharmaceutics and Kadimastem represents a bold step forward in the fight against diabetes. By focusing on multi-target diabetes treatment strategies, the companies are challenging the traditional paradigms of diabetes care and offering new hope for millions of people affected by this chronic condition.

As the global burden of diabetes continues to grow, the need for innovative, comprehensive treatment options has never been greater. The combined expertise of NLS Pharmaceutics and Kadimastem positions them to lead the way in developing therapies that go beyond symptom management to address the underlying mechanisms of the disease.

With a shared commitment to scientific excellence, patient-centred care, and long-term health outcomes, this merger has the potential to redefine what is possible in diabetes treatment—setting a new standard for how we understand, manage, and ultimately overcome this complex disease.